Researchers were surprised that late stage ovarian cancer patients responded well to an experimental carboplatin-decitabinecombination therapy, given that they had become resistant tocarboplatin. Indiana University researchers are eager to conduct alarger human study to test the two-drug combination with existingtreatment for ovarian cancer. The carboplatin-decitabine combo had a positive effect on 70% ofthe trial participants. The researchers added that they believethey have discovered biomarkers which could help better identifypatients who are most likely to respond to this therapy. Kenneth Nephew, cancer researcher in the IU Medical Sciences Program-Bloomington and atthe Indiana University Melvin and Bren Simon Cancer Center, said: "The potential that this regimen is efficacious, combiningdecitabine with the carboplatin therapy, is very exciting. It'swell tolerated and didn't have any dose-limiting toxicities. Wecould enroll patients with confidence because of these results." Ovarian cancer is the fifth largest cause of cancer death amongfemales in the USA, the researchers explained. They added that itis an aggressive and incurable cancer. Although carboplatin is seenas the most efficient drug treatment, patients with recurringovarian cancer frequently become resistant to the medication aftera couple of treatment rounds. When resistance builds, theytypically do not survive for more than one year because therearen't any effective second-line treatments around. All the 17 women involved in the clinical trial were resistant tocarboplatin, and their cancer was advancing. 12 of them saw theirtumor growth either slow down significantly, or stop altogetherafter treatment with the experimental combo. In fact, Nephew saidthe tumor became undetectable in one of the women. He added thatcancer progression resumed after about 336 days. Lead investigator Daniela Matei, M.D., who has been treatingovarian cancer patients for ten years and has performed severalhuman studies, was surprised by the high rate of positive effects.The number of women who remained in remission for at least sixmonths was surprising, she added. Matei said: "Typically in this group of patients you'd anticipate responserates of less than 5 percent and no patients would be expected tobe in remission at six months," said Matei, a physician-scientistat the IU Simon Cancer Center. "In our trial, more than half (ninewomen) of the patients were without progression at six months." This research has been funded by the NIH (National Institutes ofHealth), National cancer Institute, Walther Cancer Foundation, andthe Ovarian Cancer Research Foundation. It is estimated that approximately 200,000 women are diagnosed withovarian cancer each year globally, and 125,000 females die from thedisease. About 22,000 new diagnoses of ovarian cancer are made eachyear in the USA, where about 15,500 die from it. Unfortunately,there is no really effective means of detecting the cancer earlyon. Written by Christian Nordqvist Copyright: Medical News Today Not to be reproduced without permission of Medical News Today Additional References Citations. The e-commerce company in China offers quality products such as Water Spray Booth , China Spray Booth Parts, and more. For more , please visit Large Spray Booth today!
Related Articles -
Water Spray Booth, China Spray Booth Parts,
|